ID   MHCC97-H
AC   CVCL_4972
SY   MHCC 97-H; MHCC-97H; MHCC97H
DR   BTO; BTO:0004169
DR   GEO; GSM501782
DR   GEO; GSM936771
DR   GEO; GSM1374675
DR   GEO; GSM2551579
DR   LIMORE; MHCC97H
DR   PRIDE; PXD000529
DR   PRIDE; PXD000533
DR   PRIDE; PXD000535
DR   Wikidata; Q54905533
RX   PubMed=11819844;
RX   PubMed=15048980;
RX   PubMed=15146329;
RX   PubMed=23505090;
RX   PubMed=25690035;
RX   PubMed=25886575;
RX   PubMed=31063779;
RX   PubMed=31378681;
RX   PubMed=32884988;
WW   https://lccl.zucmanlab.com/hcc/cellLines/MHCC97H
WW   http://www.brics.ac.cn/article-template.html?articleId=411&columnId=18
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Population: Chinese.
CC   Characteristics: High metastatic potential.
CC   Doubling time: 28.79 hours (PubMed=31378681).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (PubMed=31378681).
CC   Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Genome sequenced.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
ST   Source(s): PubMed=31378681
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 8,11.3
ST   D16S539: 12
ST   D5S818: 12,13
ST   D7S820: 10
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 14
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_4971 ! MHCC97
SX   Male
AG   39Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 16
//
RX   PubMed=11819844; DOI=10.3748/wjg.v7.i5.630;
RA   Li Y., Tang Z.-Y., Ye S.-L., Liu Y.-K., Chen J., Xue Q., Chen J.,
RA   Gao D.-M., Bao W.-H.;
RT   "Establishment of cell clones with different metastatic potential from
RT   the metastatic hepatocellular carcinoma cell line MHCC97.";
RL   World J. Gastroenterol. 7:630-636(2001).
//
RX   PubMed=15048980; DOI=10.1002/pmic.200300653;
RA   Ding S.-J., Li Y., Shao X.-X., Zhou H., Zeng R., Tang Z.-Y.,
RA   Xia Q.-C.;
RT   "Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H
RT   and MHCC97-L, with different metastasis potentials.";
RL   Proteomics 4:982-994(2004).
//
RX   PubMed=15146329; DOI=10.1007/s00432-004-0564-9;
RA   Li Y., Tian B., Yang J., Zhao L., Wu X., Ye S.-L., Liu Y.-K.,
RA   Tang Z.-Y.;
RT   "Stepwise metastatic human hepatocellular carcinoma cell model system
RT   with multiple metastatic potentials established through consecutive in
RT   vivo selection and studies on metastatic characteristics.";
RL   J. Cancer Res. Clin. Oncol. 130:460-468(2004).
//
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y.,
RA   Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
//
RX   PubMed=25690035; DOI=10.3390/ijms16024209;
RA   Tian M.-M., Cheng H., Wang Z.-Q., Su N., Liu Z.-X., Sun C.-Q.,
RA   Zhen B., Hong X.-C., Xue Y., Xu P.;
RT   "Phosphoproteomic analysis of the highly-metastatic hepatocellular
RT   carcinoma cell line, MHCC97-H.";
RL   Int. J. Mol. Sci. 16:4209-4225(2015).
//
RX   PubMed=25886575; DOI=10.1186/s12885-015-1166-4;
RA   Dang H., Steinway S.N., Ding W., Rountree C.B.;
RT   "Induction of tumor initiation is dependent on CD44s in c-Met(+)
RT   hepatocellular carcinoma.";
RL   BMC Cancer 15:161.1-161.11(2015).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//
RX   PubMed=32884988; DOI=10.1016/j.gendis.2019.12.008;
RA   Lin Y.-L., Li Y.;
RT   "Study on the hepatocellular carcinoma model with metastasis.";
RL   Genes Dis. 7:336-350(2020).
//